SABCS 2025

A milestone for ET in HR+ HER2- and important follow-up…

Firstline treatment of MBC: Which strategy is best?

Axilla dissection - less is more

SERDs in early breast cancer - the new era has begun?

ALTTO trial outcome according to endocrine therapy

AI based prognostic test

PALLAS trial and ctDNA

SERDs now in adjuvant therapy

Giredestrant will replace current adjuvant therapy

Revolution in adjuvant endocrine therapy?

Surgery remains soc in low risk EBC

Safety data DB11

ctDNA analysis could optimize the approach in HER2+

Optimized endocrine therapy for premenopausal patients

sTILs with deep learning AI

Quality of live data DB11

Carboplatin in adjuvant setting of TNBC

In addition to pCR, ctDNA is prognostically relevant…

Platinum adjuvant in TNBC

El análisis del ADN libre circulante podría optimizar…

La chirurgia rimane lo standard di cura nei casi di…

SERDy we wczesnym raku piersi -początek nowej epoki?

Carboplatino nel contesto adiuvante del TNBC

Otimização da terapia: abordagens endócrinas em…

Make a hot tumor out of a cold tumor

Phase 2 combination of elacestrant with everolimus or…

ASCENT-07 a negative trial

No improvement over standard therapy

Traditional chemotherapy should not be forgotten as…

Chemotherapy-free treatment: a promising therapeutic…

Palbociclib likely delays CNS progression

Elacestrant is a good combination partner for HR+ HER2+…

The significance of SG is more clearly defined

Updated results of VIKTORIA-1

Biomarker and clinical subgroup analysis of evERA…

Elacestrant as oral endocrine backbone

CDK4/6 inhibitor + endocrine therapy remains the…

New evidence for oral SERDs

Maintenance therapy HER2+ Tucatinib as a new option

Tucatinib a new SERD in the adjuvant setting

Significant innovations in early and metastatic HER2+…

Monitoring of ILD

Nuove prove a favore dei SERD orali

Sem melhorias em relação à terapia padrão

Tucatinib, un nouveau SERD dans le cadre d'un…

Jeszcze nie czas na rezygnację z tradycyjnej…

Elacestrant come partner endocrino orale

La dinamica del ctDNA come biomarcatore di risposta

Risultati aggiornati di VIKTORIA-1